In the News

MVP: Cohen Milstein’s Carol V. Gilden

Law360

November 16, 2026

Carol V. Gilden of Cohen Milstein Sellers & Toll LLP helped secure additional shareholder value for investors who brought claims about infant formula safety and advanced investor protections in complex cross-border securities litigation, earning her a spot as one of the 2026 Law360 Securities MVPs.

Her biggest accomplishment over the past year:

Gilden said her representation of shareholders in a derivative action against Abbott Laboratories stands out.

As co-lead counsel in the Abbott shareholder derivative litigation, Gilden represented shareholders alleging that the company’s board breached its fiduciary duties by failing to adequately oversee the manufacture and sale of infant formula at its plant in Sturgis, Michigan.

The shareholders filed suit after revelations of unsanitary conditions and bacterial contamination at the facility prompted a major product recall and contributed to a nationwide infant formula shortage. The crisis led to congressional inquiries, government enforcement actions and multiple lawsuits, causing billions of dollars in operational and reputational harm to Abbott, according to the complaint.

In June, an Illinois federal court approved a settlement requiring Abbott to make $40 million in targeted capital expenditures at the Sturgis facility, along with reforms addressing product safety, regulatory compliance, complaint escalation, executive management review and board oversight.

Gilden said the case was particularly meaningful because it gave shareholders an opportunity to ensure that the company addressed the problems and operated more responsibly going forward. She said the reforms were designed to reduce the risk of similar problems recurring, particularly in an area as important to public health as infant formula manufacturing.

“I find real satisfaction in mastering the factual details in my cases and seeing how those details fit into the overall case theory, while at the same time, learning about the company’s business itself,” Gilden said.

Other notable deals she has worked on:

Gilden also pointed to her work leading cross-border securities litigation against Germany-based Bayer as a significant accomplishment. The case stemmed from Bayer’s $63 billion acquisition of Monsanto and allegations that the company misrepresented the rigor of its due diligence and legal risks associated with Monsanto’s Roundup herbicide.

The litigation raised novel questions involving American depositary receipts, which trade on U.S. exchanges in lieu of a foreign company listing its shares directly, and about whether U.S. investors who purchased the securities over the counter could pursue claims under federal securities laws.

In October 2025, the court approved a $38 million settlement. Gilden said she was particularly proud of the technical issues the litigation addressed and its implications for investors.

Even if investors purchased ADRs on U.S. over-the-counter exchanges, they can still assert their rights to recoup losses under U.S. securities laws if they were misled by that foreign company, according to Gilden.

“Ensuring that investors who purchased those instruments would be able to step in and hold Bayer accountable” was an important part of the case, she said.

. . .

What keeps her motivated:

Gilden said she’s motivated by the knowledge that her clients’ financial security often depends on her work. She represents public pension funds and Taft-Hartley pension funds — whose beneficiaries include teachers, police officers, factory workers, truck drivers and hotel employees.

“You have a teacher who’s worked their whole life, and they go to retire, and they are very much dependent on the assets in the pension fund to generate enough return to cover their pension benefits,” she said.

Gilden also said the constantly evolving nature of securities litigation keeps the practice interesting. While new technologies and business models continue to change the markets, she said, the fundamental questions in securities cases remain largely the same and human judgment is required to answer them.

Read MVP: Cohen Milstein’s Carol V. Gilden.